provides

NYSE Content Advisory: Pre-Market Update + Fortune Celebrates Cyber 60 List

NEW YORK, Oct. 30, 2025 /PRNewswire/ -- The New York Stock Exchange (NYSE) provides a daily pre-market update directly from…

4 weeks ago

China Pavilion at Osaka Expo 2025 wins the Gold Award! Unilumin provides a comprehensive multimedia solution

OSAKA, Japan, Oct. 30, 2025 /PRNewswire/ -- On the evening of October 12, 2025, the Osaka Expo 2025 witnessed a…

4 weeks ago

NYSE Content Advisory: Pre-Market Update + S&P 500 closes above 6,800 for first time

NEW YORK, Oct. 28, 2025 /PRNewswire/ -- The New York Stock Exchange (NYSE) provides a daily pre-market update directly from…

4 weeks ago

Tagvenue Launches Tagvenue PRO, Bringing AI to Help Venues Win More Bookings

Tagvenue has launched Tagvenue PRO, an AI-powered platform that simplifies venue management by automating lead responses, payment tracking, and performance…

4 weeks ago

NYSE Content Advisory: Pre-Market Update + Grayscale Celebrates Multi Asset Crypto Fund GDLC

NEW YORK, Oct. 24, 2025 /PRNewswire/ -- The New York Stock Exchange (NYSE) provides a daily pre-market update directly from…

1 month ago

ACKO Drive Launches 99 Car Spa Offer

BENGALURU, India, Oct. 24, 2025 /PRNewswire/ -- ACKO Drive has launched an irresistible ₹99 Car Spa Offer that allows people…

1 month ago

Tradewind Finance Provides USD 3.5 Million Credit Facility for Hong Kong Subsidiary of Leading German Shirt Company

MÖNCHENGLADBACH, Germany, Oct. 23, 2025 /PRNewswire/ -- International trade finance company Tradewind Finance today announced a USD 3.5 million factoring facility…

1 month ago

Light & Wonder Provides Delisting Notice to Nasdaq

LAS VEGAS--(BUSINESS WIRE)--Light & Wonder, Inc. (NASDAQ and ASX: LNW) (“Light & Wonder,” “L&W,” “we” or the “Company”) today provided…

1 month ago

NYSE Content Advisory: Pre-Market Update + International Day kicks off

NEW YORK, Oct. 23, 2025 /PRNewswire/ -- The New York Stock Exchange (NYSE) provides a daily pre-market update directly from…

1 month ago

GT Biopharma Provides Enrollment Update on GTB-3650 Phase 1 Trial in Patients with Relapsed or Refractory (r/r) CD33 Expressing Hematologic Malignancies

The formal safety review of Cohort 3 (5ug/kg/day) has been successfully completed with no safety or tolerability issues observed, allowing…

1 month ago